<SEC-DOCUMENT>0001193125-17-217755.txt : 20170629
<SEC-HEADER>0001193125-17-217755.hdr.sgml : 20170629
<ACCEPTANCE-DATETIME>20170629112832
ACCESSION NUMBER:		0001193125-17-217755
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170629
FILED AS OF DATE:		20170629
DATE AS OF CHANGE:		20170629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		17937274

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d418478d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June&nbsp;29, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED
LTD </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;&#9746; Form
40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June&nbsp;29, 2017 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PRIMA BIOMED LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">News release, &#147;Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of its American Depositary Shares,&#148; dated June&nbsp;29, 2017.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d418478dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g418478pb.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">29&nbsp;June 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED ANNOUNCES
PRICING OF US$5.0 MILLION REGISTERED DIRECT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING OF ITS AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148; or the &#147;Company&#148;) today announced it has entered into a securities
purchase agreement with certain accredited investors to purchase 2,631,268 of its American Depositary Shares (&#147;ADSs&#148;) at a purchase price per ADS of US$1.90 in a registered direct offering, for total gross proceeds of approximately
$US5.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a concurrent private placement, the Company has agreed to issue unregistered warrants to purchase up to 1,973,451 of its ADSs.
The warrants have an exercise price of US$2.50 per ADS, are exercisable immediately and will expire 5.5 years from the date of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maxim Group LLC
is acting as the sole placement agent for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registered direct offering and concurrent private placement are expected to close on or about
July&nbsp;5, 2017, subject to the satisfaction of customary closing conditions. No Prima shareholder approval is required for the proposed allotments under the securities purchase agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima intends to use the net proceeds from this offering to continue ongoing clinical development of IMP321 (e.g., the AIPAC and <FONT
STYLE="white-space:nowrap">TACTI-mel</FONT> studies), to continue preclinical research on IMP761, and for other general corporate purposes. A portion of the net proceeds may also be used to acquire or invest in businesses, products and technologies
that Prima views as complementary to its own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of ADSs described above is being made in the U.S. to U.S. investors pursuant to a shelf
registration statement on form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-211702),</FONT> as amended and previously filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on
May&nbsp;27, 2016 and declared effective on June&nbsp;17, 2016. Such ADSs are being offered only in the U.S. to U.S. investors by the means of a prospectus. A final prospectus supplement and the accompanying prospectus relating to and describing the
terms of the registered direct offering will be filed with the SEC. Copies of the preliminary prospectus supplement and the accompanying prospectus, and, when available, the final prospectus supplement and the accompanying prospectus relating to the
registered direct offering may be obtained at the SEC&#146;s website at www.sec.gov or by contacting Maxim Group LLC, 405 Lexington Avenue, 2nd&nbsp;Floor, New York, NY 10174, at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-895-3745,</FONT></FONT> or by telephone at (212) <FONT STYLE="white-space:nowrap">895-3745.</FONT> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unregistered warrants described above were offered in a private placement under Section&nbsp;4(a)(2) of the
Securities Act of 1933, as amended (the &#147;Act&#148;), and Regulation D promulgated thereunder and, along with the ADSs underlying the warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the warrants
and underlying ADSs may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from registration requirements of the Act and such applicable state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active
biotechnology company that is a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to
shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s current lead product is IMP321, based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism which
plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble <FONT STYLE="white-space:nowrap">LAG-3Ig</FONT> fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical
trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed <FONT STYLE="white-space:nowrap">TACTI-mel</FONT>
(clinicaltrials.gov identifier NCT 02676869). A number of additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products including antibodies for immune response modulation in autoimmunity and cancer are being developed by Prima&#146;s
pharmaceutical partners. Prima is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima
BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the U.S. For further information please visit www.primabiomed.com.au. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For
further information please contact: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout Group LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) <FONT
STYLE="white-space:nowrap">378-2933;</FONT> mbeck@troutgroup.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Gregorowski, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105;
mgregorowski@citadelmagnus.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g418478pb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418478pb.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4;>5@"@ H * "@ H * "C;RL 4 % !1MY6 * "@ H *
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MGA_6M:\.2F#7=)TS5;.[U#1YE<Q-%J%K!,TEJXD!4B15P1CK35^VP]O([ G
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M!A?M4^%OV.KGX=>"6^!U^UW\6KFWTBWN-#\+6]_>VUW(]O']M>^#0A4N5F)
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M5O/>02 !DOH,V]WC!(VM-$[#GHPJ'H_0#VVD,* "@ H * "@ H * "@ H *
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M@2^E9!&1>7)-S<1! 3@1R2F/J?N5#T?H![U2&% !0 4 % !_3],4!MY!0 4
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MG1O&$GAN2XFT-]7BEE;39;HP-</;^7,F&=K6W)SG_5+0!T/BCX<^"?&?A-_
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M_I0E\K#7W6%S^'Z8Q2V^0MOD']*-@3_ *!A0 4 % !0 4 % !0 4 % !0 4
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M,R'/TKKI\79O327-3DET<6OU/!Q/@GP?7;E"GB,)U_=U8Z>G-!['=V7[;GQ
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MH8&60C/RFAM1#]#](NGX?TI-[>0;!26Z&+5B"@ H * "@ H * "@ H * "@
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M7_,!B%;_ *=3_P#D1X\4^&CTU[2,>VH6W_QRE]9P_P#S_AI_>7^9/]F9BO\
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M25EM%6ZJ]RHP46]=>VO^5AGZ?3C'X5GL:;?(* /Z6Z_?S_, * "@ H * "@
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MH,H * "@V(3U/UI%$1ZGZTR6)0 4 % $)ZGZTB@H * /Z6Z_?S_, * "@ H
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MM,EB4 % !0!">I^M(H* "@#^ENOW\_S "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M%%+HX2=OFD9,_P"Q_P#&N+.S0[";'_/+5;+MTQOE%8RX5S:#<8T8-1V?,O\
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M/\@]OPHV^0HKE6_-YB@C\O8C^='Z%;>1">I^M(H* "@#^ENOW\_S "@ H *
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MTK-\#T$_][DK?W3LC](C-%%*60T')=55E;[N4_26ONS^< H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
+@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
